“Our sales expansion is yielding results and we see a consistent increase in sales as a result of our anchor clients recommending us to other medical professionals,” said Mr. Waqaas Al-Siddiq, Biotricity Founder and CEO. “Without any new device placements, the units currently at our customer sites are projected to deliver over $2 million in recurring technology fee revenues over the next 12 months. Long-term, we are a technology company with a pipeline of complimentary remote patient monitoring and pre-emptive diagnostic technologies that will allow us to leapfrog and build on our existing platform. We are just getting started.”
The Company designed its horizontal technology platform to align with the Centers for Medicare and Medicaid Services’ (CMS) stated plan to cut $57 billion in costs from US public healthcare spending by moving unnecessary inpatient care to outpatient care. This shift is increasingly made possible due to advances in remote patient monitoring (RPM) initiatives and preemptive diagnostics. It also has the potential to improve patient care and save additional lives while curbing significant healthcare costs.
Since it achieved FDA clearance, Bioflux has experienced a high adoption rate in anchor clinics since its 2018 limited market release. In 2019, the Company transitioned to full U.S. release, doubling its small sales force and expanding its footprint to 11 key states, with plans to expand further. In the month of May 2019 alone, the Company experienced a 59 percent increase in the number of devices in the field.
“Bioflux has completely transformed the way I monitor and diagnose my heart patients,” said Dr. Cesare Saponieri, MD. “The solution is designed with customizable options and high clinician usability in mind, lending itself to seamless integration with a physician’s practice. The ease with which my patients were able to use the device has made Bioflux the only choice for us
Recent BTCY News
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 06/18/2024 09:29:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 08:34:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2024 11:31:28 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/28/2024 11:22:03 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 09:00:15 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/16/2024 09:21:36 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/16/2024 04:15:26 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/15/2024 07:07:11 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/09/2024 09:28:28 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/08/2024 09:12:02 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/20/2024 10:02:19 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 02/14/2024 10:18:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 10:30:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2023 09:55:34 PM
- SWK Holdings Highlights Recent Achievements and Provides Portfolio Update • PR Newswire (US) • 10/18/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2023 12:15:04 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/19/2023 08:57:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/17/2023 12:38:08 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:26:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/04/2023 08:15:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/20/2023 09:14:24 PM
- SWK Holdings Highlights Recent Achievements and Provides Portfolio Update • PR Newswire (US) • 07/17/2023 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/05/2023 08:05:35 PM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM